Shareholders Filed a Lawsuit Against Replimune for Misleading Investors About FDA Approval

Court: D. Massachusetts

Case: 1:25-cv-12085

On July 24, 2025, REPL shareholders have filed a class action against Replimune, accusing it of overstating the viability of its lead therapy RP1 and concealing key FDA concerns about the trial design.

What is this lawsuit about?

Between November 2024 and July 2025, Replimune claimed its RP1 therapy was on track for accelerated FDA approval. However, the company hid serious issues with its IGNYTE trial, including inadequate design and patient variability.

On July 22, 2025, the FDA rejected RP1’s application, citing insufficient evidence. REPL collapsed 77.24% to close at $2.80.

What can you do to recover your losses now?

We’re keeping track of all updates and will notify REPL investors about potential recovery.

More than 600 companies are currently facing securities class action lawsuits, and over 100 are already paying settlements. Connect your brokerage account to automatically check which ones you may have missed.